{"timestamp": "2026-01-21T07:21:43.824637", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"白紫+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"<0.91 ng/ml (2022-10-12)\",\"CA125\":\"933.00 U/ml (2022-12-29)\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging\",\"DIAGNOSIS\":{\"components\":[\"High-grade adenocarcinoma involving full-thickness intestinal wall\",\"Lymph node metastasis (4/15)\",\"Peritoneal/rectal/vaginal involvement described\"],\"histology\":\"透明细胞癌; 肠壁全层见高级别腺癌\",\"laterality\":\"Unknown\",\"primary\":\"卵巢癌复发\",\"site\":\"Ovary\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Unknown\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6\",\"end_date\":\"2022-08-17\",\"intent\":\"Unknown\",\"line\":\"1L\",\"regimen\":\"白紫+卡铂\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"56\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"56\",\"end_date\":\"2022-08-17\",\"evidence\":\"Rise in CA125/CA19-9 on 2022-10-12\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2022-10-12\",\"line\":\"1L\",\"start_date\":\"Unknown\",\"status\":\"Resistant\"}],\"PLATINUM_PFI_CURRENT\":\"56\",\"PLATINUM_STATUS\":\"Resistant\",\"PLATINUM_STATUS_CURRENT\":\"Resistant\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2022-10-12\",\"evidence\":\"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence\",\"type\":\"Biochemical\"},\"SCENE\":\"Platinum_resistant_relapse\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2022-03-28\",\"performed\":\"Yes\",\"procedure\":\"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]},\"VISIT_DATE\":\"2023-01-03\",\"first_relapse_date\":\"2022-10-12\",\"last_platinum_end_date\":\"2022-08-17\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"14.90\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"89.60\"},{\"date\":\"2022-11-17\",\"flag\":\"↑\",\"value\":\"403\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"7.16\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"77.20\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"↑\",\"value\":\"87.90\"},{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"59.70\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"AFP\",\"history\":[{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"}],\"latest\":{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"}],\"milestones\":[{\"date\":\"2022-03-28\",\"description\":\"Primary cytoreductive surgery performed\",\"type\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-10-12\",\"description\":\"Biochemical relapse with rising tumor markers\",\"type\":\"Relapse\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"6 cycles of 白紫+卡铂, last 2022-08-17\",\"last_admin_date\":\"2022-08-17\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"白紫+卡铂\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"Tumor size ~7x4x2.5 cm\",\"Bilateral margins negative\",\"Pericolic lymph nodes 4/15 positive\",\"One tumor nodule (posterior bladder)\"],\"date\":\"2022-03-28\",\"diagnosis\":\"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\",\"grade\":\"High-grade\",\"ihc\":[{\"marker\":\"MLH1\",\"result\":\"+\"},{\"marker\":\"MSH6\",\"result\":\"+\"},{\"marker\":\"MSH2\",\"result\":\"+\"},{\"marker\":\"PMS2\",\"result\":\"+\"},{\"marker\":\"ER\",\"result\":\"partial+\"},{\"marker\":\"PR\",\"result\":\"few weak+\"},{\"marker\":\"P53\",\"result\":\"+/-\"},{\"marker\":\"WT1\",\"result\":\"-\"},{\"marker\":\"Ki-67\",\"result\":\"60%+\"},{\"marker\":\"HNF1B\",\"result\":\"+\"},{\"marker\":\"NapsinA\",\"result\":\"focal+\"},{\"marker\":\"P16\",\"result\":\"+\"},{\"marker\":\"PAX8\",\"result\":\"+\"},{\"marker\":\"SALL4\",\"result\":\"-\"},{\"marker\":\"ZBTB16\",\"result\":\"-\"}],\"involvement_sites\":[\"Rectosigmoid colon\",\"Left retroperitoneum\",\"Vagina\",\"Pericolic lymph nodes\",\"Posterior bladder nodule\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）\",\"sample_type\":\"Surgical resection\",\"site\":\"Partial rectosigmoid + left retroperitoneal tumor + partial vagina\",\"tumor_size\":\"7 x 4 x 2.5 cm\",\"uncertainty_or_missing\":[\"BRCA/HRD testing not reported\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Pelvis\"],\"date\":\"2022-10-24\",\"findings\":[\"Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules\"],\"impression\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Liver\"],\"date\":\"2022-10-25\",\"findings\":[\"Multiple intrahepatic nodules, some new compared to prior\"],\"impression\":\"Probable metastases in liver\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Pelvis; sacrum; right iliac bone\"],\"date\":\"2022-12-30\",\"findings\":[\"Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar\"],\"impression\":\"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Liver; spleen\"],\"date\":\"2022-12-30\",\"findings\":[\"Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct\"],\"impression\":\"Progression of hepatic metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]}}", "final_output": "Final Assessment:\nPatient has platinum-resistant recurrent ovarian clear cell carcinoma with multi-site progression (pelvis, liver, bone) confirmed on recent imaging [@2022-12-29 | MR], [@2022-12-29 | CT] and a germline ATM p.Y316C variant [@OH2203828 | Genomics]. Key uncertainties include current functional status and metabolic disease extent.\n\nCore Treatment Strategy:\n- Obtain urgent PET/CT for metabolic staging of progressive lesions before finalizing therapy.\n- Initiate non-platinum chemotherapy for platinum-resistant recurrence per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] after confirming ECOG and renal/liver function [@20221229|8300002 | LAB].\n- Schedule biopsy of a new lesion (e.g., hepatic) for updated molecular profiling.\n- Provide symptom-directed care (e.g., pain management) while awaiting definitive treatment.\n\nChange Triggers:\n- If PET/CT shows unexpected limited oligometastatic disease, consider local ablative therapy alongside systemic treatment.\n- If biopsy reveals a new actionable mutation, integrate matched targeted therapy with chemotherapy.\n\n---\n## References\n\n### Guidelines\n\n[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n  Document: nccn_ovariancancer_v3_2025__v00000000, Page 22\n  Content: Survivorship)\nRecurrent\ndiseaset\nHormonal...\n\n### Literature\n\n### Clinical Trials\n\n### Clinical Reports\n\n[@2022-12-29 | MR]\n  MR ID: 2022-12-29\n\n[@2022-12-29 | CT]\n  CT ID: 2022-12-29\n\n[@OH2203828 | Genomics]\n  Genomics ID: OH2203828 | Date: 2022-04-18\n  Content: ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1...\n\n[@20221229|8300002 | LAB]\n  LAB ID: 20221229|8300002 | Date: 2022-12-29\n  Content: 天冬氨酸氨基转移酶 43.0 U/L (AST) 游离脂肪酸 0.09 mmol/L (NEFA) 谷氨酸脱氢酶...\n", "initial_ops": {"chair": "- Platinum-resistant recurrence (PFI 56 days) with progressive pelvic/hepatic disease [@2022-12-29 | CT], [@2022-12-29 | MR]. Next line requires non-platinum chemo category per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Germline ATM p.Y316C variant found [@OH2203828 | Genomics]; clinical impact uncertain. BRCA1/2, HRD negative, limiting PARPi options.\n- Rising CA125 to 933 U/ml [@20221229|9703212 | LAB] and new right iliac bone lesion confirm progression; need symptom/pain assessment and staging update.", "oncologist": "- Redistribution therapy for recurrent platinum-sensitive clear cell post upfront chemo, tumor markers rising (CA125 933 U/ml [@20221229|9703212 | LAB]) & documented metastasis on recent scans.\n- Germline ATM p.Y316C [@OH2203828 | Genomics] detected; tumor is BRCA1/2 negative & HRD-negative. Consider implications for DDR-targeted treatment categories [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Update full organ function (renal/hepatic from Dec 29 [@20221229|8300002 | LAB]) and confirm ECOG for regimen selection today.", "radiologist": "*   Pelvic MRI shows progressive presacral recurrence (53×44mm, increased size/hypogeneity) with adjacent sacral and new right iliac bone involvement [@2022-12-29 | MR].\n*   CT demonstrates progressive hepatic metastases (nodules increased in number/size) and possible splenic infarct [@2022-12-29 | CT].\n*   Imaging confirms multi-site disease progression, consistent with platinum-resistant recurrence requiring next-line therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].", "pathologist": "- Histology suggests ovarian clear cell carcinoma involving colon/retroperitoneum/vagina, high-grade [@2022-03-28 | PATHOLOGY].\n- Comprehensive NGS shows ATM germline mutation p.Y316C; BRCA1/2 negative [@OH2203828 | Genomics]. HRD negative [@OH2203828 | Genomics].\n- For high-grade serous carcinoma, HRD status guides PARPi therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], but histology unclear.", "nuclear": "- PET-based metabolic patterns are unknown; requires PET/CT imaging update for current metabolic staging [@2022-12-29 | MR] [@2022-12-29 | CT].\n- Multiple non-PET imaging reports show progressive pelvic and hepatic disease consistent with recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Current PET data is missing; it is critical for identifying metabolically active sites, which may alter disease assessment and follow-up."}, "merged_summary": "**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing (2022) reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n1.  **Confirm Clinical Status:** Obtain updated ECOG, symptom/pain assessment, and renal/liver function.\n2.  **Metabolic Staging:** Schedule an **urgent PET/CT** to define the metabolic activity of progressive lesions (pelvic, hepatic, bone) and guide further management.\n3.  **Initiate Treatment:** Proceed with a **non-platinum chemotherapy** regimen per NCCN guidelines for platinum-resistant recurrence, pending the above confirmations.\n4.  **Update Molecular Profile:** Obtain a **biopsy of a new/progressive lesion** (e.g., hepatic) for updated molecular profiling. Current genomic data (2022) may not reflect the biology of the recurrent tumor.", "final_round_ops": {"Round 1": {"chair": "- Proceed with non-platinum chemotherapy for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] after confirming ECOG status and renal/liver function [@20221229|8300002 | LAB].\n- Obtain urgent PET/CT to define metabolic activity of progressive pelvic/hepatic/bone lesions [@2022-12-29 | MR], [@2022-12-29 | CT] before finalizing therapy.\n- Pathologist advises biopsy of new lesion to update molecular profile; current ATM p.Y316C variant [@OH2203828 | Genomics] may not reflect current tumor biology.", "oncologist": "- Finalize non-platinum chemotherapy plan for platinum-resistant recurrence (PFI 56d), guided by NCCN [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending current ECOG/pain assessment.\n- Urgently request PET/CT for metabolic staging of presacral, iliac bone [@2022-12-29 | MR] & liver lesions [@2022-12-29 | CT] per nuclear medicine.\n- Consider biopsy for updated molecular profiling, as ATM p.Y316C [@OH2203828 | Genomics] from primary may not reflect recurrent tumor biology per pathologist.", "radiologist": "- Obtain PET/CT for metabolic staging given progressive pelvic and hepatic disease [@2022-12-29 | MR] [@2022-12-29 | CT].\n- Start non-platinum chemotherapy per NCCN for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Schedule new biopsy for updated molecular profiling; prior data from 2022 [@OH2203828 | Genomics].", "pathologist": "- Await updated clinical status (ECOG, symptoms) and urgent PET/CT to define active disease extent for staging [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Prioritize non-platinum chemotherapy per NCCN guidance for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending functional status.\n- Obtain biopsy of new lesion (e.g., hepatic) for updated molecular profiling, as 2022 genomic data [@OH2203828 | Genomics] may not reflect current tumor biology.", "nuclear": "- Plan PET/CT urgently for metabolic staging of known disease: presacral mass, iliac bone [@2022-12-29 | MR], and hepatic lesions [@2022-12-29 | CT].\n- PET findings may alter surveillance planning in recurrent disease, as per imaging guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Await updated PET for current metabolic status; this will define metabolically active sites to guide biopsy and future monitoring."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient has germline ATM p.Y316C variant [@OH2203828 | Genomics]; clarify if lab details included neoadjuvant or prior therapy response.", "radiologist": "Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@2022-12-29 | MR], and hepatic metastases [@2022-12-29 | CT] for complete staging and to evaluate for occult disease.", "pathologist": null, "nuclear": null}, "oncologist": {"chair": "Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH2203828 | Genomics] and rising CA125 [@20221229|9703212 | LAB]. Guidelines recommend non-platinum chemo [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]; does ATM variant influence DDR-targeted therapy selection for this histology?", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": "Imaging reports show clear disease progression; however, for optimal planning, an updated PET/CT is crucial for comprehensive metabolic staging and to rule out occult disease.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 2022-03-28 tumor sample [@OH2203828 | Genomics], not reflecting the current 2023-01-03 recurrent tumor's biology. New biopsy for updated molecular profiling is critical.", "oncologist": "The existing HRD/BRCA result from 2022 is for a clear cell carcinoma [@OH2203828 | Genomics]. NCCN PARPi/HRD guidance is primarily for high-grade serous histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], limiting applicability here.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": "Missing critical PET/CT data for current metabolic staging; needed to define active disease extent, which can meaningfully alter staging and surveillance plans, per NCCN guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Platinum-resistant recurrence (PFI 56 days) with progressive pelvic/hepatic disease [@2022-12-29 | CT], [@2022-12-29 | MR]. Next line requires non-platinum chemo category per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Germline ATM p.Y316C variant found [@OH2203828 | Genomics]; clinical impact uncertain. BRCA1/2, HRD negative, limiting PARPi options.\n- Rising CA125 to 933 U/ml [@20221229|9703212 | LAB] and new right iliac bone lesion confirm progression; need symptom/pain assessment and staging update.", "timestamp": "2026-01-21T07:17:46.751705"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"radiologist\",\"message\":\"Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@2022-12-29 | MR], and hepatic metastases [@2022-12-29 | CT] for complete staging and to evaluate for occult disease.\",\"why\":\"missing\"},{\"target\":\"oncologist\",\"message\":\"Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient has germline ATM p.Y316C variant [@OH2203828 | Genomics]; clarify if lab details included neoadjuvant or prior therapy response.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-21T07:18:40.750381"}, {"role": "chair", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] ging and to rule out occult disease. | pathologist->chair(unspecified): Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 2022-03-28 tumor sample [@OH2203828 | Genomics], not reflecting the current 2023-01-03 recurrent tumor's biology. New biopsy for updated molecular profiling is critical. | pathologist->oncologist(unspecified): The existing HRD/BRCA result from 2022 is for a clear cell carcinoma [@OH2203828 | Genomics]. NCCN PARPi/HRD guidance is primarily for high-grade serous histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], limiting applicability here. | nuclear->chair(missing): Missing critical PET/CT data for current metabolic staging; needed to define active disease extent, which can meaningfully alter staging and surveillance plans, per NCCN guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient has germline ATM p.Y316C variant [@OH2203828 | Genomics]; clarify if lab details included neoadjuvant or prior therapy response. | chair→radiologist: Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@2022-12-29 | MR], and hepatic metastases [@2022-12-29 | CT] for complete staging and to evaluate for occult disease. | oncologist→chair: Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH2203828 | Genomics] and rising CA125 [@20221229|9703212 | LAB]. Guidelines recommend non-platinum chemo [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]; does ATM variant influence DDR-targeted therapy selection for this histology?\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Proceed with non-platinum chemotherapy for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] after confirming ECOG status and renal/liver function [@20221229|8300002 | LAB].\n- Obtain urgent PET/CT to define metabolic activity of progressive pelvic/hepatic/bone lesions [@2022-12-29 | MR], [@2022-12-29 | CT] before finalizing therapy.\n- Pathologist advises biopsy of new lesion to update molecular profile; current ATM p.Y316C variant [@OH2203828 | Genomics] may not reflect current tumor biology.", "timestamp": "2026-01-21T07:19:33.872860"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\n# MDT DISCUSSION SUMMARY\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing (2022) reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n1.  **Confirm Clinical Status:** Obtain updated ECOG, symptom/pain assessment, and renal/liver function.\n2.  **Metabolic Staging:** Schedule an **urgent PET/CT** to define the metabolic activity of progressive lesions (pelvic, hepatic, bone) and guide further management.\n3.  **Initiate Treatment:** Proceed with a **non-platinum chemotherapy** regimen per NCCN guidelines for platinum-resistant recurrence, pending the above confirmations.\n4.  **Update Molecular Profile:** Obtain a **biopsy of a new/progressive lesion** (e.g., hepatic) for updated molecular profiling. Current genomic data (2022) may not reflect the biology of the recurrent tumor.\n\n# INITIAL EXPERT OPINIONS\n- chair: - Platinum-resistant recurrence (PFI 56 days) with progressive pelvic/hepatic disease [@2022-12-29 | CT], [@2022-12-29 | MR]. Next line requires non-platinum chemo category per [@guideline:nccn_ovaria\n- oncologist: - Redistribution therapy for recurrent platinum-sensitive clear cell post upfront chemo, tumor markers rising (CA125 933 U/ml [@20221229|9703212 | LAB]) & documented metastasis on recent scans.\n- Germ\n- radiologist: *   Pelvic MRI shows progressive presacral recurrence (53×44mm, increased size/hypogeneity) with adjacent sacral and new right iliac bone involvement [@2022-12-29 | MR].\n*   CT demonstrates progressiv\n- pathologist: - Histology suggests ovarian clear cell carcinoma involving colon/retroperitoneum/vagina, high-grade [@2022-03-28 | PATHOLOGY].\n- Comprehensive NGS shows ATM germline mutation p.Y316C; BRCA1/2 negativ\n- nuclear: - PET-based metabolic patterns are unknown; requires PET/CT imaging update for current metabolic staging [@2022-12-29 | MR] [@2022-12-29 | CT].\n- Multiple non-PET imaging reports show progressive pelv\n\n# DISCUSSION INTERACTIONS\nRound 1: R1T1: chair→oncologist: Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient | R1T1: chair→radiologist: Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@20 | R1T1: oncologist→chair: Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH22038 | R1T1: radiologist→chair: Imaging reports show clear disease progression; however, for optimal planning, an updated PET/CT is  | R1T1: pathologist→chair: Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 202\n\n\n\n# FINAL REFINED PLANS (All experts, all rounds)\n{\n  \"Round 1\": {\n    \"chair\": \"- Proceed with non-platinum chemotherapy for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] after confirming ECOG status and renal/liver function [@20221229|8300002 | LAB].\\n- Obtain urgent PET/CT to define metabolic activity of progressive pelvic/hepatic/bone lesions [@2022-12-29 | MR], [@2022-12-29 | CT] before finalizing therapy.\\n- Pathologist advises biopsy of new lesion to update molecular profile; current ATM p.Y316C variant [@OH2203828 | Genomics] may not reflect current tumor biology.\",\n    \"oncologist\": \"- Finalize non-platinum chemotherapy plan for platinum-resistant recurrence (PFI 56d), guided by NCCN [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending current ECOG/pain assessment.\\n- Urgently request PET/CT for metabolic staging of presacral, iliac bone [@2022-12-29 | MR] & liver lesions [@2022-12-29 | CT] per nuclear medicine.\\n- Consider biopsy for updated molecular profiling, as ATM p.Y316C [@OH2203828 | Genomics] from primary may not reflect recurrent tumor biology per pathologist.\",\n    \"radiologist\": \"- Obtain PET/CT for metabolic staging given progressive pelvic and hepatic disease [@2022-12-29 | MR] [@2022-12-29 | CT].\\n- Start non-platinum chemotherapy per NCCN for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Schedule new biopsy for updated molecular profiling; prior data from 2022 [@OH2203828 | Genomics].\",\n    \"pathologist\": \"- Await updated clinical status (ECOG, symptoms) and urgent PET/CT to define active disease extent for staging [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Prioritize non-platinum chemotherapy per NCCN guidance for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending functional status.\\n- Obtain biopsy of new lesion (e.g., hepatic) for updated molecular profiling, as 2022 genomic data [@OH2203828 | Genomics] may not reflect current tumor biology.\",\n    \"nuclear\": \"- Plan PET/CT urgently for metabolic staging of known disease: presacral mass, iliac bone [@2022-12-29 | MR], and hepatic lesions [@2022-12-29 | CT].\\n- PET findings may alter surveillance planning in recurrent disease, as per imaging guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Await updated PET for current metabolic status; this will define metabolically active sites to guide biopsy and future monitoring.\"\n  }\n}\n\n# CLINICAL TRIAL RECOMMENDATION (from assistant)\nTrial Recommendation:\n- id: None\n- name: None\n- Reason: No trial matches the patient's platinum-resistant recurrent ovarian clear cell carcinoma with available biomarker data.\n- Missing eligibility confirmations (0-2 items):\n  - None\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@OH2203828|2022-04-18 | Genomics], [@2022-12-29 | MR], [@2022-12-29 | CT]). Note: Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.\n- If a clinical trial has been recommended by the assistant and you judge it appropriate for the patient, mention it naturally within Core Treatment Strategy or Change Triggers and cite it using [@trial | trial_id] format (e.g., [@trial | 350]).\n- If experts disagree, pick the safest plan and state the key uncertainty.\n- You MUST consider the MDT discussion summary and interactions above when making your decision.\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words \"if X, then adjust management from A to B\" >\n- < ≤20 words \"if X, then adjust management from A to B\" >\n", "assistant_reply": "Final Assessment:\nPatient has platinum-resistant recurrent ovarian clear cell carcinoma with multi-site progression (pelvis, liver, bone) confirmed on recent imaging [@2022-12-29 | MR], [@2022-12-29 | CT] and a germline ATM p.Y316C variant [@OH2203828 | Genomics]. Key uncertainties include current functional status and metabolic disease extent.\n\nCore Treatment Strategy:\n- Obtain urgent PET/CT for metabolic staging of progressive lesions before finalizing therapy.\n- Initiate non-platinum chemotherapy for platinum-resistant recurrence per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] after confirming ECOG and renal/liver function [@20221229|8300002 | LAB].\n- Schedule biopsy of a new lesion (e.g., hepatic) for updated molecular profiling.\n- Provide symptom-directed care (e.g., pain management) while awaiting definitive treatment.\n\nChange Triggers:\n- If PET/CT shows unexpected limited oligometastatic disease, consider local ablative therapy alongside systemic treatment.\n- If biopsy reveals a new actionable mutation, integrate matched targeted therapy with chemotherapy.", "timestamp": "2026-01-21T07:21:43.818694"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Redistribution therapy for recurrent platinum-sensitive clear cell post upfront chemo, tumor markers rising (CA125 933 U/ml [@20221229|9703212 | LAB]) & documented metastasis on recent scans.\n- Germline ATM p.Y316C [@OH2203828 | Genomics] detected; tumor is BRCA1/2 negative & HRD-negative. Consider implications for DDR-targeted treatment categories [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Update full organ function (renal/hepatic from Dec 29 [@20221229|8300002 | LAB]) and confirm ECOG for regimen selection today.", "timestamp": "2026-01-21T07:17:53.651022"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH2203828 | Genomics] and rising CA125 [@20221229|9703212 | LAB]. Guidelines recommend non-platinum chemo [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]; does ATM variant influence DDR-targeted therapy selection for this histology?\",\"why\":\"new\"}]}", "timestamp": "2026-01-21T07:18:48.488278"}, {"role": "oncologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] ging and to rule out occult disease. | pathologist->chair(unspecified): Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 2022-03-28 tumor sample [@OH2203828 | Genomics], not reflecting the current 2023-01-03 recurrent tumor's biology. New biopsy for updated molecular profiling is critical. | pathologist->oncologist(unspecified): The existing HRD/BRCA result from 2022 is for a clear cell carcinoma [@OH2203828 | Genomics]. NCCN PARPi/HRD guidance is primarily for high-grade serous histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], limiting applicability here. | nuclear->chair(missing): Missing critical PET/CT data for current metabolic staging; needed to define active disease extent, which can meaningfully alter staging and surveillance plans, per NCCN guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient has germline ATM p.Y316C variant [@OH2203828 | Genomics]; clarify if lab details included neoadjuvant or prior therapy response. | chair→radiologist: Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@2022-12-29 | MR], and hepatic metastases [@2022-12-29 | CT] for complete staging and to evaluate for occult disease. | oncologist→chair: Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH2203828 | Genomics] and rising CA125 [@20221229|9703212 | LAB]. Guidelines recommend non-platinum chemo [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]; does ATM variant influence DDR-targeted therapy selection for this histology?\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Finalize non-platinum chemotherapy plan for platinum-resistant recurrence (PFI 56d), guided by NCCN [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending current ECOG/pain assessment.\n- Urgently request PET/CT for metabolic staging of presacral, iliac bone [@2022-12-29 | MR] & liver lesions [@2022-12-29 | CT] per nuclear medicine.\n- Consider biopsy for updated molecular profiling, as ATM p.Y316C [@OH2203828 | Genomics] from primary may not reflect recurrent tumor biology per pathologist.", "timestamp": "2026-01-21T07:19:43.766959"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "*   Pelvic MRI shows progressive presacral recurrence (53×44mm, increased size/hypogeneity) with adjacent sacral and new right iliac bone involvement [@2022-12-29 | MR].\n*   CT demonstrates progressive hepatic metastases (nodules increased in number/size) and possible splenic infarct [@2022-12-29 | CT].\n*   Imaging confirms multi-site disease progression, consistent with platinum-resistant recurrence requiring next-line therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].", "timestamp": "2026-01-21T07:17:59.210406"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Imaging reports show clear disease progression; however, for optimal planning, an updated PET/CT is crucial for comprehensive metabolic staging and to rule out occult disease.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-21T07:18:57.451159"}, {"role": "radiologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] ging and to rule out occult disease. | pathologist->chair(unspecified): Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 2022-03-28 tumor sample [@OH2203828 | Genomics], not reflecting the current 2023-01-03 recurrent tumor's biology. New biopsy for updated molecular profiling is critical. | pathologist->oncologist(unspecified): The existing HRD/BRCA result from 2022 is for a clear cell carcinoma [@OH2203828 | Genomics]. NCCN PARPi/HRD guidance is primarily for high-grade serous histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], limiting applicability here. | nuclear->chair(missing): Missing critical PET/CT data for current metabolic staging; needed to define active disease extent, which can meaningfully alter staging and surveillance plans, per NCCN guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient has germline ATM p.Y316C variant [@OH2203828 | Genomics]; clarify if lab details included neoadjuvant or prior therapy response. | chair→radiologist: Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@2022-12-29 | MR], and hepatic metastases [@2022-12-29 | CT] for complete staging and to evaluate for occult disease. | oncologist→chair: Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH2203828 | Genomics] and rising CA125 [@20221229|9703212 | LAB]. Guidelines recommend non-platinum chemo [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]; does ATM variant influence DDR-targeted therapy selection for this histology?\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Obtain PET/CT for metabolic staging given progressive pelvic and hepatic disease [@2022-12-29 | MR] [@2022-12-29 | CT].\n- Start non-platinum chemotherapy per NCCN for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Schedule new biopsy for updated molecular profiling; prior data from 2022 [@OH2203828 | Genomics].", "timestamp": "2026-01-21T07:20:26.218267"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Histology suggests ovarian clear cell carcinoma involving colon/retroperitoneum/vagina, high-grade [@2022-03-28 | PATHOLOGY].\n- Comprehensive NGS shows ATM germline mutation p.Y316C; BRCA1/2 negative [@OH2203828 | Genomics]. HRD negative [@OH2203828 | Genomics].\n- For high-grade serous carcinoma, HRD status guides PARPi therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], but histology unclear.", "timestamp": "2026-01-21T07:18:07.879803"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 2022-03-28 tumor sample [@OH2203828 | Genomics], not reflecting the current 2023-01-03 recurrent tumor's biology. New biopsy for updated molecular profiling is critical.\",\"why\":\"critical\"},{\"target\":\"oncologist\",\"message\":\"The existing HRD/BRCA result from 2022 is for a clear cell carcinoma [@OH2203828 | Genomics]. NCCN PARPi/HRD guidance is primarily for high-grade serous histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], limiting applicability here.\",\"why\":\"critical\"}]}", "timestamp": "2026-01-21T07:19:05.545597"}, {"role": "pathologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] ging and to rule out occult disease. | pathologist->chair(unspecified): Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 2022-03-28 tumor sample [@OH2203828 | Genomics], not reflecting the current 2023-01-03 recurrent tumor's biology. New biopsy for updated molecular profiling is critical. | pathologist->oncologist(unspecified): The existing HRD/BRCA result from 2022 is for a clear cell carcinoma [@OH2203828 | Genomics]. NCCN PARPi/HRD guidance is primarily for high-grade serous histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], limiting applicability here. | nuclear->chair(missing): Missing critical PET/CT data for current metabolic staging; needed to define active disease extent, which can meaningfully alter staging and surveillance plans, per NCCN guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient has germline ATM p.Y316C variant [@OH2203828 | Genomics]; clarify if lab details included neoadjuvant or prior therapy response. | chair→radiologist: Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@2022-12-29 | MR], and hepatic metastases [@2022-12-29 | CT] for complete staging and to evaluate for occult disease. | oncologist→chair: Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH2203828 | Genomics] and rising CA125 [@20221229|9703212 | LAB]. Guidelines recommend non-platinum chemo [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]; does ATM variant influence DDR-targeted therapy selection for this histology?\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Await updated clinical status (ECOG, symptoms) and urgent PET/CT to define active disease extent for staging [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Prioritize non-platinum chemotherapy per NCCN guidance for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending functional status.\n- Obtain biopsy of new lesion (e.g., hepatic) for updated molecular profiling, as 2022 genomic data [@OH2203828 | Genomics] may not reflect current tumor biology.", "timestamp": "2026-01-21T07:20:35.412774"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- PET-based metabolic patterns are unknown; requires PET/CT imaging update for current metabolic staging [@2022-12-29 | MR] [@2022-12-29 | CT].\n- Multiple non-PET imaging reports show progressive pelvic and hepatic disease consistent with recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Current PET data is missing; it is critical for identifying metabolically active sites, which may alter disease assessment and follow-up.", "timestamp": "2026-01-21T07:18:16.230634"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Missing critical PET/CT data for current metabolic staging; needed to define active disease extent, which can meaningfully alter staging and surveillance plans, per NCCN guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\",\"why\":\"missing\"}]}", "timestamp": "2026-01-21T07:19:13.722550"}, {"role": "nuclear", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] ging and to rule out occult disease. | pathologist->chair(unspecified): Pathology clarification: Molecular panel (HRD negative, BRCA wild-type, ATM p.Y316C) was for the 2022-03-28 tumor sample [@OH2203828 | Genomics], not reflecting the current 2023-01-03 recurrent tumor's biology. New biopsy for updated molecular profiling is critical. | pathologist->oncologist(unspecified): The existing HRD/BRCA result from 2022 is for a clear cell carcinoma [@OH2203828 | Genomics]. NCCN PARPi/HRD guidance is primarily for high-grade serous histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], limiting applicability here. | nuclear->chair(missing): Missing critical PET/CT data for current metabolic staging; needed to define active disease extent, which can meaningfully alter staging and surveillance plans, per NCCN guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Confirm ECOG status (likely 0-2) and current symptoms before proceeding to chemotherapy. The patient has germline ATM p.Y316C variant [@OH2203828 | Genomics]; clarify if lab details included neoadjuvant or prior therapy response. | chair→radiologist: Request urgent PET/CT to assess metabolic activity of the presacral mass, new iliac bone lesion [@2022-12-29 | MR], and hepatic metastases [@2022-12-29 | CT] for complete staging and to evaluate for occult disease. | oncologist→chair: Need chair guidance: platinum-resistant CCC recurrence (PFI 56d) with germline ATM p.Y316C [@OH2203828 | Genomics] and rising CA125 [@20221229|9703212 | LAB]. Guidelines recommend non-platinum chemo [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]; does ATM variant influence DDR-targeted therapy selection for this histology?\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Plan PET/CT urgently for metabolic staging of known disease: presacral mass, iliac bone [@2022-12-29 | MR], and hepatic lesions [@2022-12-29 | CT].\n- PET findings may alter surveillance planning in recurrent disease, as per imaging guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Await updated PET for current metabolic status; this will define metabolically active sites to guide biopsy and future monitoring.", "timestamp": "2026-01-21T07:21:06.181371"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Platinum-resistant recurrence (PFI 56 days) with progressive pelvic/hepatic disease [@2022-12-29 | CT], [@2022-12-29 | MR]. Next line requires non-platinum chemo category per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Germline ATM p.Y316C variant found [@OH2203828 | Genomics]; clinical impact uncertain. BRCA1/2, HRD negative, limiting PARPi options.\\n- Rising CA125 to 933 U/ml [@20221229|9703212 | LAB] and new right iliac bone lesion confirm progression; need symptom/pain assessment and staging update.\",\"oncologist\":\"- Redistribution therapy for recurrent platinum-sensitive clear cell post upfront chemo, tumor markers rising (CA125 933 U/ml [@20221229|9703212 | LAB]) & documented metastasis on recent scans.\\n- Germline ATM p.Y316C [@OH2203828 | Genomics] detected; tumor is BRCA1/2 negative & HRD-negative. Consider implications for DDR-targeted treatment categories [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Update full organ function (renal/hepatic from Dec 29 [@20221229|8300002 | LAB]) and confirm ECOG for regimen selection today.\",\"radiologist\":\"*   Pelvic MRI shows progressive presacral recurrence (53×44mm, increased size/hypogeneity) with adjacent sacral and new right iliac bone involvement [@2022-12-29 | MR].\\n*   CT demonstrates progressive hepatic metastases (nodules increased in number/size) and possible splenic infarct [@2022-12-29 | CT].\\n*   Imaging confirms multi-site disease progression, consistent with platinum-resistant recurrence requiring next-line therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\",\"pathologist\":\"- Histology suggests ovarian clear cell carcinoma involving colon/retroperitoneum/vagina, high-grade [@2022-03-28 | PATHOLOGY].\\n- Comprehensive NGS shows ATM germline mutation p.Y316C; BRCA1/2 negative [@OH2203828 | Genomics]. HRD negative [@OH2203828 | Genomics].\\n- For high-grade serous carcinoma, HRD status guides PARPi therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18], but histology unclear.\",\"nuclear\":\"- PET-based metabolic patterns are unknown; requires PET/CT imaging update for current metabolic staging [@2022-12-29 | MR] [@2022-12-29 | CT].\\n- Multiple non-PET imaging reports show progressive pelvic and hepatic disease consistent with recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Current PET data is missing; it is critical for identifying metabolically active sites, which may alter disease assessment and follow-up.\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.", "timestamp": "2026-01-21T07:18:28.172383"}, {"role": "assistant", "user_message": "You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.\n\nCURRENT_MDT_GLOBAL_KNOWLEDGE:\n[MDT_GLOBAL_KNOWLEDGE]\n**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The clinical impact of the identified germline ATM p.Y316C variant on treatment selection (e.g., for DDR-targeted therapies) is uncertain.\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n- Obtain updated clinical assessment (ECOG, symptoms/pain) and laboratory workup (renal/hepatic function).\n- Schedule a PET/CT for comprehensive metabolic staging.\n- Discuss the implications of the ATM variant and histology for targeted therapy options within the context of non-platinum chemotherapy regimens for platinum-resistant recurrence.\n\nROUND_1_FINAL_PLANS_JSON:\n{\"chair\":\"- Proceed with non-platinum chemotherapy for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22] after confirming ECOG status and renal/liver function [@20221229|8300002 | LAB].\\n- Obtain urgent PET/CT to define metabolic activity of progressive pelvic/hepatic/bone lesions [@2022-12-29 | MR], [@2022-12-29 | CT] before finalizing therapy.\\n- Pathologist advises biopsy of new lesion to update molecular profile; current ATM p.Y316C variant [@OH2203828 | Genomics] may not reflect current tumor biology.\",\"oncologist\":\"- Finalize non-platinum chemotherapy plan for platinum-resistant recurrence (PFI 56d), guided by NCCN [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending current ECOG/pain assessment.\\n- Urgently request PET/CT for metabolic staging of presacral, iliac bone [@2022-12-29 | MR] & liver lesions [@2022-12-29 | CT] per nuclear medicine.\\n- Consider biopsy for updated molecular profiling, as ATM p.Y316C [@OH2203828 | Genomics] from primary may not reflect recurrent tumor biology per pathologist.\",\"radiologist\":\"- Obtain PET/CT for metabolic staging given progressive pelvic and hepatic disease [@2022-12-29 | MR] [@2022-12-29 | CT].\\n- Start non-platinum chemotherapy per NCCN for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Schedule new biopsy for updated molecular profiling; prior data from 2022 [@OH2203828 | Genomics].\",\"pathologist\":\"- Await updated clinical status (ECOG, symptoms) and urgent PET/CT to define active disease extent for staging [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Prioritize non-platinum chemotherapy per NCCN guidance for platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], pending functional status.\\n- Obtain biopsy of new lesion (e.g., hepatic) for updated molecular profiling, as 2022 genomic data [@OH2203828 | Genomics] may not reflect current tumor biology.\",\"nuclear\":\"- Plan PET/CT urgently for metabolic staging of known disease: presacral mass, iliac bone [@2022-12-29 | MR], and hepatic lesions [@2022-12-29 | CT].\\n- PET findings may alter surveillance planning in recurrent disease, as per imaging guidance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\\n- Await updated PET for current metabolic status; this will define metabolically active sites to guide biopsy and future monitoring.\"}", "assistant_reply": "**Key Knowledge:**\n- Platinum-resistant recurrence (PFI 56 days) with confirmed multi-site progression (pelvic, hepatic, new iliac bone lesion) and rising CA125 (933 U/ml). NCCN guidelines indicate a need for non-platinum chemotherapy.\n- Pathology is consistent with high-grade ovarian clear cell carcinoma. Comprehensive genomic testing (2022) reveals a germline ATM p.Y316C variant. Tumor is BRCA1/2 and HRD negative, limiting PARPi options.\n- Imaging (CT, MRI) confirms progressive disease in the pelvis (enlarged presacral mass with bone involvement) and liver.\n\n**Controversies:**\n- The relevance of HRD testing/PARPi guidance (from NCCN) is unclear given the patient's clear cell carcinoma histology, which differs from high-grade serous carcinoma.\n\n**Missing Info:**\n- Current ECOG performance status and updated assessment of symptoms/pain.\n- Updated PET/CT imaging to define current metabolic activity and complete staging.\n- Recent full organ function (renal/hepatic) to inform regimen selection.\n\n**Working Plan:**\n1.  **Confirm Clinical Status:** Obtain updated ECOG, symptom/pain assessment, and renal/liver function.\n2.  **Metabolic Staging:** Schedule an **urgent PET/CT** to define the metabolic activity of progressive lesions (pelvic, hepatic, bone) and guide further management.\n3.  **Initiate Treatment:** Proceed with a **non-platinum chemotherapy** regimen per NCCN guidelines for platinum-resistant recurrence, pending the above confirmations.\n4.  **Update Molecular Profile:** Obtain a **biopsy of a new/progressive lesion** (e.g., hepatic) for updated molecular profiling. Current genomic data (2022) may not reflect the biology of the recurrent tumor.", "timestamp": "2026-01-21T07:21:17.634877"}], "trial_selector": [{"role": "trial_selector", "user_message": "You are an MDT assistant for gynecologic oncology clinical trial matching.\n\nCRITICAL BEHAVIOR:\n- You MUST NOT ask the user any questions.\n- You MUST NOT request additional information.\n- You MUST NOT output anything except the required template.\n- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.\n- If eligibility is unclear due to missing key facts, you MUST output None.\n\nPATIENT CASE (facts only; do not infer):\n# ORIGINAL CASE JSON\n{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"白紫+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"<0.91 ng/ml (2022-10-12)\",\"CA125\":\"933.00 U/ml (2022-12-29)\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging\",\"DIAGNOSIS\":{\"components\":[\"High-grade adenocarcinoma involving full-thickness intestinal wall\",\"Lymph node metastasis (4/15)\",\"Peritoneal/rectal/vaginal involvement described\"],\"histology\":\"透明细胞癌; 肠壁全层见高级别腺癌\",\"laterality\":\"Unknown\",\"primary\":\"卵巢癌复发\",\"site\":\"Ovary\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Unknown\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6\",\"end_date\":\"2022-08-17\",\"intent\":\"Unknown\",\"line\":\"1L\",\"regimen\":\"白紫+卡铂\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"56\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"56\",\"end_date\":\"2022-08-17\",\"evidence\":\"Rise in CA125/CA19-9 on 2022-10-12\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2022-10-12\",\"line\":\"1L\",\"start_date\":\"Unknown\",\"status\":\"Resistant\"}],\"PLATINUM_PFI_CURRENT\":\"56\",\"PLATINUM_STATUS\":\"Resistant\",\"PLATINUM_STATUS_CURRENT\":\"Resistant\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2022-10-12\",\"evidence\":\"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence\",\"type\":\"Biochemical\"},\"SCENE\":\"Platinum_resistant_relapse\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2022-03-28\",\"performed\":\"Yes\",\"procedure\":\"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]},\"VISIT_DATE\":\"2023-01-03\",\"first_relapse_date\":\"2022-10-12\",\"last_platinum_end_date\":\"2022-08-17\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"14.90\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"89.60\"},{\"date\":\"2022-11-17\",\"flag\":\"↑\",\"value\":\"403\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"7.16\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"77.20\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[{\"date\":\"2022-08-15\",\"flag\":\"↑\",\"value\":\"87.90\"},{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"59.70\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"AFP\",\"history\":[{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"}],\"latest\":{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"}],\"milestones\":[{\"date\":\"2022-03-28\",\"description\":\"Primary cytoreductive surgery performed\",\"type\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-10-12\",\"description\":\"Biochemical relapse with rising tumor markers\",\"type\":\"Relapse\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"6 cycles of 白紫+卡铂, last 2022-08-17\",\"last_admin_date\":\"2022-08-17\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"白紫+卡铂\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"Tumor size ~7x4x2.5 cm\",\"Bilateral margins negative\",\"Pericolic lymph nodes 4/15 positive\",\"One tumor nodule (posterior bladder)\"],\"date\":\"2022-03-28\",\"diagnosis\":\"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\",\"grade\":\"High-grade\",\"ihc\":[{\"marker\":\"MLH1\",\"result\":\"+\"},{\"marker\":\"MSH6\",\"result\":\"+\"},{\"marker\":\"MSH2\",\"result\":\"+\"},{\"marker\":\"PMS2\",\"result\":\"+\"},{\"marker\":\"ER\",\"result\":\"partial+\"},{\"marker\":\"PR\",\"result\":\"few weak+\"},{\"marker\":\"P53\",\"result\":\"+/-\"},{\"marker\":\"WT1\",\"result\":\"-\"},{\"marker\":\"Ki-67\",\"result\":\"60%+\"},{\"marker\":\"HNF1B\",\"result\":\"+\"},{\"marker\":\"NapsinA\",\"result\":\"focal+\"},{\"marker\":\"P16\",\"result\":\"+\"},{\"marker\":\"PAX8\",\"result\":\"+\"},{\"marker\":\"SALL4\",\"result\":\"-\"},{\"marker\":\"ZBTB16\",\"result\":\"-\"}],\"involvement_sites\":[\"Rectosigmoid colon\",\"Left retroperitoneum\",\"Vagina\",\"Pericolic lymph nodes\",\"Posterior bladder nodule\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）\",\"sample_type\":\"Surgical resection\",\"site\":\"Partial rectosigmoid + left retroperitoneal tumor + partial vagina\",\"tumor_size\":\"7 x 4 x 2.5 cm\",\"uncertainty_or_missing\":[\"BRCA/HRD testing not reported\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Pelvis\"],\"date\":\"2022-10-24\",\"findings\":[\"Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules\"],\"impression\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Liver\"],\"date\":\"2022-10-25\",\"findings\":[\"Multiple intrahepatic nodules, some new compared to prior\"],\"impression\":\"Probable metastases in liver\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Pelvis; sacrum; right iliac bone\"],\"date\":\"2022-12-30\",\"findings\":[\"Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar\"],\"impression\":\"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"Liver; spleen\"],\"date\":\"2022-12-30\",\"findings\":[\"Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct\"],\"impression\":\"Progression of hepatic metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive\",\"regimen_or_test\":\"Surgical resection\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17\",\"event_type\":\"Chemo\",\"key_result\":\"Post-chemo tumor markers reduced on 2022-08-15\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Rising tumor markers indicating recurrence\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 77.20 U/ml; CA125 89.60 U/ml\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-10-24\",\"description\":\"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement\",\"event_type\":\"Imaging\",\"key_result\":\"Presacral lesion and pelvic mesenteric nodules, possible metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT shows multiple liver nodules, some new compared to prior\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple hepatic metastatic nodules\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Markedly elevated tumor markers consistent with progression\",\"event_type\":\"Lab\",\"key_result\":\"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L\",\"regimen_or_test\":\"Tumor markers\"},{\"date\":\"2022-12-30\",\"description\":\"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Progression of pelvic and hepatic metastatic disease\",\"regimen_or_test\":\"MRI pelvis; CT abdomen\"}]}}\n\n# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)\n⚠️ COMPREHENSIVE NGS PANEL (~20,000 genes) - INTERPRETATION RULES:\n• '未检出' (not detected) = NO pathogenic mutation found\n• '（视为阴性）' (considered negative) = NO pathogenic mutation found\n• '阴性' (negative) = negative result\n• Genes with specific variants (e.g., 'NM_xxx:exon:c.xxx:p.xxx') = POSITIVE mutation\n• If a gene is NOT mentioned, it means NO pathogenic mutation (comprehensive panel)\n\n## Mutation Report 1 (ID: OH2203828, Date: 2022-04-18)\nATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）\n\n\nAVAILABLE TRIALS (compact; use id/name exactly as shown):\n[\n  {\n    \"id\": \"345\",\n    \"name\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2、3、4L\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳\",\n    \"sponsor\": \"江苏康宁杰瑞生物制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、HER2 表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"王 涛\"\n    ],\n    \"phones\": [\n      \"18721569326\"\n    ],\n    \"_raw\": {\n      \"id\": \"345\",\n      \"项目名称\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n      \"医生\": \"李佳佳\",\n      \"试验治疗/用药\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"江苏康宁杰瑞生物制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2、3、4L\",\n      \"入组排除标准\": \"1、HER2 表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"王 涛\"\n      ],\n      \"联系电话\": [\n        \"18721569326\"\n      ]\n    }\n  },\n  {\n    \"id\": \"346\",\n    \"name\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"朱 俊\",\n    \"sponsor\": \"阿斯利康投资（中国）有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"江文燕\"\n    ],\n    \"phones\": [\n      \"15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"346\",\n      \"项目名称\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n      \"医生\": \"朱 俊\",\n      \"试验治疗/用药\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"阿斯利康投资（中国）有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"江文燕\"\n      ],\n      \"联系电话\": [\n        \"15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"348\",\n    \"name\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n    \"phase\": \"I期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n    \"sponsor\": \" 上海美雅珂生物技术有限责任公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n    \"key_inclusion\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"杨 珂\"\n    ],\n    \"phones\": [\n      \"17774582517\"\n    ],\n    \"_raw\": {\n      \"id\": \"348\",\n      \"项目名称\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n      \"医生\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n      \"试验治疗/用药\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n      \"期别\": \"I期\",\n      \"申请单位\": \" 上海美雅珂生物技术有限责任公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n      \"联系人\": [\n        \"杨 珂\"\n      ],\n      \"联系电话\": [\n        \"17774582517\"\n      ]\n    }\n  },\n  {\n    \"id\": \"350\",\n    \"name\": \"评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\",\n    \"phase\": \"Ⅰb/Ⅱ 期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"吴 勇、刘汝娇 、高水平\",\n    \"sponsor\": \"成都百利多特生物药业有限责任公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"单臂研究\\n\\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"李 想\"\n    ],\n    \"phones\": [\n      \"17703993082\"\n    ],\n    \"_raw\": {\n      \"id\": \"350\",\n      \"项目名称\": \"评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\",\n      \"医生\": \"吴 勇、刘汝娇 、高水平\",\n      \"试验治疗/用药\": \"单臂研究<br />\\r\\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）<br />\",\n      \"期别\": \"Ⅰb/Ⅱ 期\",\n      \"申请单位\": \"成都百利多特生物药业有限责任公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤\",\n      \"联系人\": [\n        \"李 想\"\n      ],\n      \"联系电话\": [\n        \"17703993082\"\n      ]\n    }\n  },\n  {\n    \"id\": \"351\",\n    \"name\": \" 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳、刘汝娇\",\n    \"sponsor\": \"西藏海思科制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）\",\n    \"key_inclusion\": \"既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"张倩野\"\n    ],\n    \"phones\": [\n      \"18627004197\"\n    ],\n    \"_raw\": {\n      \"id\": \"351\",\n      \"项目名称\": \" 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究\",\n      \"医生\": \"李佳佳、刘汝娇\",\n      \"试验治疗/用药\": \"HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"西藏海思科制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；\",\n      \"联系人\": [\n        \"张倩野\"\n      ],\n      \"联系电话\": [\n        \"18627004197\"\n      ]\n    }\n  },\n  {\n    \"id\": \"353\",\n    \"name\": \"在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"刘汝娇\",\n    \"sponsor\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n    \"lead_or_participation\": \"参与（天津市肿瘤医院 郝继辉）\",\n    \"treatment\": \"注射用西罗莫司（白蛋白结合型）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"刘 涵\"\n    ],\n    \"phones\": [\n      \"19109628595\"\n    ],\n    \"_raw\": {\n      \"id\": \"353\",\n      \"项目名称\": \"在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究\",\n      \"医生\": \"刘汝娇\",\n      \"试验治疗/用药\": \"注射用西罗莫司（白蛋白结合型）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n      \"牵头/参与\": \"参与（天津市肿瘤医院 郝继辉）\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者\",\n      \"联系人\": [\n        \"刘 涵\"\n      ],\n      \"联系电话\": [\n        \"19109628595\"\n      ]\n    }\n  },\n  {\n    \"id\": \"354\",\n    \"name\": \"一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"吴 勇\",\n    \"sponsor\": \" 浙江道尔生物科技有限公司\",\n    \"lead_or_participation\": \"参与（组长单位：上海市肺科医院）\",\n    \"treatment\": \"注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）\",\n    \"key_inclusion\": \"1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗\\n\\n2、HPV 16+\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"浦东/郭 伟 、徐汇/江文艳\"\n    ],\n    \"phones\": [\n      \"13156793722、15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"354\",\n      \"项目名称\": \"一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究\",\n      \"医生\": \"吴 勇\",\n      \"试验治疗/用药\": \"注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \" 浙江道尔生物科技有限公司\",\n      \"牵头/参与\": \"参与（组长单位：上海市肺科医院）\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗<br />\\r\\n2、HPV 16+<br />\",\n      \"联系人\": [\n        \"浦东/郭 伟 、徐汇/江文艳\"\n      ],\n      \"联系电话\": [\n        \"13156793722、15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"358\",\n    \"name\": \"评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2-3线\",\n    \"biomarker\": null,\n    \"doctor\": \"张 剑 、李佳佳\",\n    \"sponsor\": \"江苏康宁杰瑞生物制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"徐汇/牛紫嫣 浦东/刘雅琦\"\n    ],\n    \"phones\": [\n      \"15638299516 18636833967 \"\n    ],\n    \"_raw\": {\n      \"id\": \"358\",\n      \"项目名称\": \"评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n      \"医生\": \"张 剑 、李佳佳\",\n      \"试验治疗/用药\": \"JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"江苏康宁杰瑞生物制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2-3线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者\",\n      \"联系人\": [\n        \"徐汇/牛紫嫣 浦东/刘雅琦\"\n      ],\n      \"联系电话\": [\n        \"15638299516 18636833967 \"\n      ]\n    }\n  },\n  {\n    \"id\": \"359\",\n    \"name\": \"SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \">2L\",\n    \"biomarker\": null,\n    \"doctor\": \"张 剑 、李佳佳 、刘汝娇、 高水平\",\n    \"sponsor\": \"苏州盛迪亚生物医药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、组织学确诊的子宫颈癌；\\n\\n2、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"黄洋洋\"\n    ],\n    \"phones\": [\n      \"13226861415\"\n    ],\n    \"_raw\": {\n      \"id\": \"359\",\n      \"项目名称\": \"SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究\",\n      \"医生\": \"张 剑 、李佳佳 、刘汝娇、 高水平\",\n      \"试验治疗/用药\": \"SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"苏州盛迪亚生物医药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \">2L\",\n      \"入组排除标准\": \"1、组织学确诊的子宫颈癌；<br />\\r\\n2、标准治疗失败或无标准治疗患者<br />\",\n      \"联系人\": [\n        \"黄洋洋\"\n      ],\n      \"联系电话\": [\n        \"13226861415\"\n      ]\n    }\n  },\n  {\n    \"id\": \"361\",\n    \"name\": \"一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳\",\n    \"sponsor\": \"Bayer Consumer Care AG\",\n    \"lead_or_participation\": \"参与\",\n    \"treatment\": \"单臂研究\\n\\nBAY 2927088（TKI，靶向HER2）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者；\\n\\n2、HER2激活突变（本院或认证的机构）；\\n\\n3、需提供肿瘤组织切片。\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"李金山\"\n    ],\n    \"phones\": [\n      \"18893190113 \"\n    ],\n    \"_raw\": {\n      \"id\": \"361\",\n      \"项目名称\": \"一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究\",\n      \"医生\": \"李佳佳\",\n      \"试验治疗/用药\": \"单臂研究<br />\\r\\nBAY 2927088（TKI，靶向HER2）<br />\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"Bayer Consumer Care AG\",\n      \"牵头/参与\": \"参与\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者；<br />\\r\\n2、HER2激活突变（本院或认证的机构）；<br />\\r\\n3、需提供肿瘤组织切片。<br />\",\n      \"联系人\": [\n        \"李金山\"\n      ],\n      \"联系电话\": [\n        \"18893190113 \"\n      ]\n    }\n  }\n]\n\nDECISION RULE (be conservative):\nRecommend ONE trial ONLY IF ALL are true:\n1) Cancer type / primary site clearly matches.\n2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).\n3) Required biomarker/subtype is explicitly present in case text (if trial requires it).\n4) No more than 2 critical eligibility confirmations remain.\n\nIf ANY of the above is not satisfied -> output None.\n\nOUTPUT TEMPLATE (EXACT; no extra text):\n\nTrial Recommendation:\n- id: <trial id or None>\n- name: <trial name or None>\n- Reason: <1 short sentence>\n- Missing eligibility confirmations (0-2 items):\n  - item1 (or \"None\")\n  - item2", "assistant_reply": "Trial Recommendation:\n- id: None\n- name: None\n- Reason: No trial matches the patient's platinum-resistant recurrent ovarian clear cell carcinoma with available biomarker data.\n- Missing eligibility confirmations (0-2 items):\n  - None", "timestamp": "2026-01-21T07:21:34.985077"}]}, "trace_events": [{"ts": "2026-01-21T07:15:55.948541", "event": "pipeline_start", "payload": {"visit_time": "2023-01-03 08:53:29.260000", "meta_info": "340123197709263626"}}, {"ts": "2026-01-21T07:15:55.948908", "event": "case_fingerprint", "payload": {"case_fingerprint": "2a31f255c155"}}, {"ts": "2026-01-21T07:15:56.214091", "event": "reports_loaded", "payload": {"lab_n": 92, "img_n": 10, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-04 08:53:29"}}, {"ts": "2026-01-21T07:16:54.840870", "event": "reports_selected", "payload": {"lab": {"chair": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "oncologist": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "oncologist": [], "radiologist": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "pathologist": [], "nuclear": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2203828|2022-04-18"], "oncologist": ["OH2203828|2022-04-18"], "radiologist": [], "pathologist": ["OH2203828|2022-04-18"], "nuclear": []}}}, {"ts": "2026-01-21T07:16:54.846739", "event": "rag_key_facts", "payload": {"facts": "DIAGNOSIS: primary=卵巢癌复发; histology=透明细胞癌; 肠壁全层见高级别腺癌; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=<0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）"}}, {"ts": "2026-01-21T07:17:18.244875", "event": "rag_query", "payload": {"query": "Recurrent platinum-resistant ovarian clear cell carcinoma with liver, pelvic, and possible bone metastases; HRD-negative, BRCA-negative, and ATM germline p.Y316C variant; histology: clear cell carcinoma"}}, {"ts": "2026-01-21T07:17:18.244885", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-21T07:17:18.244887", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-21T07:17:18.244889", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-21T07:17:38.306373", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-21T07:17:38.306683", "event": "mdt_initial_opinion_role_start", "payload": {"role": "chair", "order": 1}}, {"ts": "2026-01-21T07:17:46.751727", "event": "mdt_initial_opinion_role_end", "payload": {"role": "chair", "chars": 529}}, {"ts": "2026-01-21T07:17:46.751785", "event": "mdt_initial_opinion_role_start", "payload": {"role": "oncologist", "order": 2}}, {"ts": "2026-01-21T07:17:53.651029", "event": "mdt_initial_opinion_role_end", "payload": {"role": "oncologist", "chars": 543}}, {"ts": "2026-01-21T07:17:53.651060", "event": "mdt_initial_opinion_role_start", "payload": {"role": "radiologist", "order": 3}}, {"ts": "2026-01-21T07:17:59.210416", "event": "mdt_initial_opinion_role_end", "payload": {"role": "radiologist", "chars": 493}}, {"ts": "2026-01-21T07:17:59.210455", "event": "mdt_initial_opinion_role_start", "payload": {"role": "pathologist", "order": 4}}, {"ts": "2026-01-21T07:18:07.879820", "event": "mdt_initial_opinion_role_end", "payload": {"role": "pathologist", "chars": 416}}, {"ts": "2026-01-21T07:18:07.879868", "event": "mdt_initial_opinion_role_start", "payload": {"role": "nuclear", "order": 5}}, {"ts": "2026-01-21T07:18:16.230664", "event": "mdt_initial_opinion_role_end", "payload": {"role": "nuclear", "chars": 451}}, {"ts": "2026-01-21T07:21:17.635370", "event": "mdt_discussion_end", "payload": {"merged_chars": 1677}}, {"ts": "2026-01-21T07:21:17.637216", "event": "trial_matching_start", "payload": {"trials_json_path": "files/all_trials_filtered.json"}}, {"ts": "2026-01-21T07:21:34.985136", "event": "trial_matching_end", "payload": {"recommended": false}}, {"ts": "2026-01-21T07:21:34.985154", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-21T07:21:43.821024", "event": "final_output_end", "payload": {"final_output_chars": 1728}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
